finance
Akari Therapeutics Stock Falls After 255 Percent Weekly Gain
Akari Therapeutics PLC shares declined on Tuesday following a 255 percent surge late last week. The movement came after the company reported preclinical results for its AKTX-101 asset in KRAS-mutated pancreatic cancer models.
May 26, 7:41 AM·1m read1 source
manilatimes.netAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Akari Therapeutics PLC (NASDAQ: AKTX) stock declined Tuesday after rising 255 percent in the prior session. The pullback followed the release of preclinical laboratory data on the company's asset AKTX-101.
The data showed that AKTX-101 produced synergistic cell-killing activity when combined with the KRAS inhibitor adagrasib. The effect appeared in cell lines carrying KRAS G12D and KRAS G12C mutations. The same synergy was not observed when adagrasib was tested with first-in-class TROP2 antibody-drug conjugates that use traditional topoisomerase I inhibitor payloads.
Those combinations instead showed antagonistic effects. The company presented the contrast between the two payload types in its report on the findings.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationLimited · 1 source
